27.01
27.01 (0%)
As of Apr 17, 2025
Collegium Pharmaceutical, Inc [COLL]
Source:
Company Overview
Collegium Pharmaceutical, Inc is a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of moderate to severe pain and attention deficit hyperactivity disorder (“ADHD”), consisting of Jornay PM (“Jornay”), Belbuca, Xtampza ER, Nucynta ER and Nucynta IR (collectively the “Nucynta Products”), and Symproic, in the United States.
| Country | United States |
| Headquarters | stoughton |
| Phone Number | (781) 713-3699 |
| Industry | manufacturing |
| CEO | Joseph Ciaffoni |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $631.4 |
| Operating Profit | $169.9 |
| Net Income | $69.2 |
| Net Cash | $-143.4 |
Profit Ratios
| Gross Margin | $377.3 |
| Operating Margin | 26.9 |
| Profit as % of Revenues | 545.4% |
| Profit as % of Assets | 4.9% |
| Profit as % of Stockholder Equity | 30.2% |
Management Effectiveness
| Return on Equity | 30.2% |
| Return on Assets | 4.2% |
| Turnover Ratio | 45% |
| EBITA | $169.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,663.6 |
| Total Liabilities | $1,434.7 |
| Operating Cash Flow | $205 |
| Investing Cash Flow | $-287.8 |
| Financing Cash Flow | $-60.6 |
